SCHEMBL4497230

SCHEMBL4497230

O=C(NCc1cccnc1)c1ccc2c(c1)ncn2-c1ccc(OCc2ccc(OC(F)(F)F)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 4/20 0.53
RECQL P46063 1/20 0.53
TP53 P04637 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
GPR132 Q9UNW8 1/20 0.48
MAPK1 P28482 2/20 0.48
ROCK2 O75116 1/20 0.47
TSHR P16473 1/20 0.47
NPC1 O15118 1/20 0.46
GFER P55789 1/20 0.46
HPGD P15428 4/20 0.46
ALDH1A1 P00352 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1379465 0.94 LMNA (0.53) HTTSMN1; SMN2LMNARECQLTP53
SCHEMBL1378946 0.93 HTT (0.58) HTTSMN1; SMN2LMNARECQLTP53
SCHEMBL1380049 0.91 HTT (0.58) HTTSMN1; SMN2LMNARECQLTP53
SCHEMBL1382395 0.91 HTT (0.58) HTTSMN1; SMN2LMNARECQLTP53
SCHEMBL1380715 0.90 SMN1; SMN2 (0.57) HTTSMN1; SMN2LMNARECQLTP53
SCHEMBL1378499 0.90 HTT (0.58) HTTSMN1; SMN2LMNARECQLTP53
SCHEMBL1378885 0.90 TP53 (0.65) HTTSMN1; SMN2LMNARECQLTP53
SCHEMBL1378566 0.89 ROCK2 (0.52) HTTSMN1; SMN2LMNARECQLTP53
SCHEMBL2964769 0.89 SMN1; SMN2 (0.53) HTTSMN1; SMN2LMNARECQLMEN1
SCHEMBL4507029 0.89 HTT (0.57) HTTSMN1; SMN2LMNARECQLTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US claimed
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP disclosed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors KIT, CHUK, TNNI3K HTT 4544/4885SMN1; SMN2 2900/4885LMNA 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.